非奈利酮在4期慢性肾脏病合并2型糖尿病参与者中的结局:FIDELITY亚组分析
该FIDELITY亚组分析纳入890例4期慢性肾脏病(eGFR<30 ml/min/1.73 m²)合并2型糖尿病参与者,评估非奈利酮对心血管复合结局和肾脏复合结局的影响。非奈利酮组心血管复合结局风险的风险比为0.78(95%CI 0.57-1.07);肾脏复合结局仅在2年内显示保护效应,之后关联方向不一致。白蛋白尿和eGFR下降速率 consistently 降低,不良事件两组平衡,高钾血症最常见但导致永久停药的发生率低。
要点
- 4期慢性肾脏病合并2型糖尿病参与者中,非奈利酮心血管复合结局风险的风险比为0.78(95%CI 0.57-1.07)。
- 肾脏复合结局比例风险假设不满足,保护效应仅见于2年内,之后关联方向不一致。
- 非奈利酮组白蛋白尿和eGFR下降速率持续降低,高钾血症发生率26% vs 13%,但永久停药率低(3% vs 2%)。
核心结论
- 在4期慢性肾脏病参与者中,非奈利酮的心血管获益和安全性特征与整体FIDELITY人群一致,白蛋白尿和eGFR下降速率也一致,但对肾脏复合结局的效应随时间不一致。
研究设计与样本
- FIDELITY预先设定的汇总分析(FIDELIO-DKD和FIGARO-DKD)的亚组分析,纳入4期慢性肾脏病(eGFR<30 ml/min/1.73 m²)合并2型糖尿病参与者。
- 共13023例参与者中890例(7%)为4期慢性肾脏病。
主要发现
- 非奈利酮组心血管复合结局(心血管死亡、非致死性心肌梗死、非致死性卒中或心力衰竭住院)风险的风险比为0.78(95%CI 0.57-1.07)。
- 肾脏复合结局(肾衰竭、eGFR较基线持续下降≥57%或肾脏病死亡)的比例风险假设在整个研究期间不满足,保护效应仅显示至2年,之后关联方向不一致,非奈利酮组与安慰剂组风险差异随时间观察到精度损失。
- 非奈利酮组与安慰剂组相比,白蛋白尿和eGFR下降速率持续降低。
- 不良事件在治疗组间平衡;高钾血症是最常见的不良事件(4期慢性肾脏病:非奈利酮组26% vs 安慰剂组13%),但导致永久停药的高钾血症发生率低(4期慢性肾脏病:非奈利酮组3% vs 安慰剂组2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 肾脏复合结局的比例风险假设在整个研究期间不满足,保护效应仅显示至2年,之后关联方向不一致,非奈利酮组与安慰剂组风险差异随时间观察到精度损失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with stage 4 CKD and type 2 diabetes have limited treatment options to reduce their persistent cardiovascular and kidney risk. In Finerenone in Chronic Kidney Disease and Type 2 Diabetes (FIDELITY), a prespecified pooled analysis of Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD), finerenone improved heart-kidney outcomes in participants with CKD and type 2 diabetes. METHODS: This FIDELITY subgroup analysis investigated the effects of finerenone in participants with stage 4 CKD (eGFR <30 ml/min per 1.73 m 2 ). Efficacy outcomes included a cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and a kidney composite (kidney failure, sustained ≥57% decrease in eGFR from baseline, or kidney disease death). RESULTS: Of 13,023 participants, 890 (7%) had stage 4 CKD. The hazard ratio for risk of cardiovascular composite outcome with finerenone versus placebo was 0.78 (95% confidence interval, 0.57 to 1.07). The kidney composite outcome proportional hazards assumption was not met for the overall study period, with a protective effect only shown up to 2 years, after which the direction of association was inconsistent, and an observed loss of precision over time incurred on finerenone versus placebo risk differences. Nonetheless, albuminuria and rate of eGFR decline were consistently reduced with finerenone versus placebo. Adverse events were balanced between treatment arms. Hyperkalemia was the most common adverse event reported (stage 4 CKD: 26% and 13% for finerenone versus placebo, respectively); however, the incidence of hyperkalemia leading to permanent discontinuation was low (stage 4 CKD: 3% and 2% for finerenone versus placebo, respectively). CONCLUSIONS: The cardiovascular benefits and safety profile of finerenone in participants with stage 4 CKD were consistent with the overall FIDELITY population; this was also the case for albuminuria and the rate of eGFR decline. The effects on the composite kidney outcome were not consistent over time.
引用
- Sarafidis P, Agarwal R, Pitt B, et al. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023. PMID: 36927680. doi:10.2215/CJN.0000000000000149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。